New obesity guidelines for kids address when medication is an option
Obesity Canada's first update to the pediatric obesity management guideline in almost 20 years was published in the Canadian Medical Association Journal this week.
The organization's scientific director, Dr. Sanjeev Sockalingam, says both the scientific understanding and societal impact of obesity have since changed dramatically.
Sockalingam says one of the major changes is the development of GLP-1 agonist drugs — such as Ozempic, Wegovy or Mounjaro — for weight loss that have been studied in adolescents 12 years of age and over.
He says the starting point for treating obesity should be a discussion with patients and their families about what their goals are and what nutrition, exercise and psychological support is needed.
Sockalingam says if those actions aren't working then medication or bariatric surgery might be considered, but only after discussing the benefits and risks with the patient and their family.
If medications are used, it's critical that nutrition, exercise and other needed treatments are also continued, the guideline says.
The discussion about using medication should also include the fact that more research is still needed to determine the long-term effects, Sockalingam said.
The guideline was developed by a committee of experts from several disciplines who evaluated multiple research studies on obesity. Children and adolescents, as well as their families, also gave their input about what would be helpful for them.
Obesity Canada says about one in four children age 11 years and younger and one in three adolescents between 12 and 17 years of age are considered overweight or obese.
Family doctors and other health-care providers should go beyond measuring their patients' body-mass index, or BMI, when assessing them, the guideline says.
That means talking to kids and their families about specific goals other than weight loss, from managing blood pressure and cholesterol to improving their quality of life.
It also emphasizes that health-care providers should avoid using stigmatizing language.
"Some children with obesity and families have a history of negative interactions with health-care providers, including feeling blamed and shamed," the guideline says.
"It is important to use encouraging, supportive words and language during clinical conversations."
The Canadian Paediatric Society says it is reviewing the new guideline.
'Obesity is a complex and multi-faceted issue that demands an individualized response. We appreciate the time and care Obesity Canada put into the updated recommendations," the society said in an emailed statement.
"Our subject matter experts are carefully reviewing the guidelines as we consider adopting them.'
Sockalingam, who is also the psychosocial director for the University Health Network's bariatric surgery program in Toronto, said obesity is a chronic disease and should be treated that way.
"There are struggles across health professions, including some primary-care providers that still are not aware that obesity is a chronic disease and that it requires a multimodal treatment," he said.
Dr. Mélanie Henderson, who was on the pediatric obesity guideline development committee, said providing comprehensive treatment often requires improved access to other specialists, such as psychologists, nutritionists, kinesiologists and social workers.
"(It's) lifestyle and behavioural interventions that's the heart of pediatric obesity management and it remains so, even if you have to increase your modalities by adding pharmacotherapy or bariatric surgery," said Henderson, who is a pediatric endocrinologist and researcher at CHU Sainte-Justine in Montreal.
Those interventions need to be tailored to each child, she said. Rather than giving "sort of blind recommendations that you need to be active one hour per day," talk about what activities the child is interested in and determine what's doable for the family.
Mental health support may be needed to help children and teens deal with problems associated with obesity, including bullying and stigma, she said.
"Obesity is not a personal choice," Henderson said, noting the importance of "helping kids find the confidence in themselves to make the changes, to not get discouraged."
This report by The Canadian Press was first published April 15, 2025.
Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content.
Nicole Ireland, The Canadian Press
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
11 hours ago
- Time Business News
The Role of Sleep Quality in Mounjaro Weight Loss Outcomes: A UK Perspective
In recent years, the conversation around weight management in the UK has broadened beyond diet and exercise. Increasingly, factors such as emotional wellbeing, hormonal health, and sleep quality are being recognised as significant contributors to sustainable weight outcomes. This shift has coincided with the emergence of newer medications developed primarily for managing Type 2 Diabetes—one of the most prominent being Mounjaro (tirzepatide). While primarily indicated for blood glucose control, many individuals prescribed Mounjaro have observed notable weight loss benefits as a secondary outcome. However, to fully optimise these effects, supporting lifestyle factors like sleep quality should not be overlooked. This article explores how sleep interacts with the body's metabolic processes and how it may influence Mounjaro weight loss outcomes, particularly for those managing their health in the UK context. Mounjaro, the brand name for tirzepatide, is a once-weekly injectable medication prescribed for the management of Type 2 Diabetes. What sets Mounjaro apart from other medications is its dual action on two key gut hormones: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). These hormones play a crucial role in regulating insulin secretion, appetite, and digestion. This dual receptor activity means the tirzepatide mechanism of action not only helps with glycaemic control but also reduces hunger and delays gastric emptying. These effects can contribute to modest weight loss, which has drawn attention from researchers and patients alike. Mounjaro is typically administered via the Mounjaro injection, and it is available in pen devices such as the MounjaroKwikPen, offering ease of use for patients prescribed the medication. Sleep is often seen as downtime, but metabolically, it is an active and essential process. Poor sleep quality or insufficient sleep disrupts hormonal balances that regulate hunger, insulin sensitivity, and stress. Specifically, sleep deprivation reduces leptin, the hormone responsible for satiety, while increasing ghrelin, which stimulates appetite. Moreover, lack of rest impairs insulin sensitivity, potentially leading to elevated blood glucose levels and increased fat storage. For individuals managing Type 2 Diabetes or trying to support their metabolism, sleep becomes an integral part of the equation. Given Mounjaro's role in blood sugar control and appetite regulation, there is growing interest in whether optimising sleep can enhance the medication's effectiveness, particularly in achieving sustained metabolic improvements. While clinical data directly linkingsleep quality and tirzepatide efficacy is still emerging, there is a strong biological rationale for synergy. The GLP-1 and GIP receptors targeted by Mounjaro are influenced by circadian rhythms—our body's internal clock. Poor sleep can disrupt these rhythms, potentially blunting hormonal responses. On the other hand, consistent and restorative sleep may allow these metabolic pathways to function optimally, thereby complementing the pharmacological effects of Mounjaro weight loss treatment. Moreover, fatigue from poor sleep may decrease physical activity levels or increase cravings for high-calorie foods, indirectly reducing the benefits seen from Mounjaro. Like all prescription medications, Mounjaro side effects vary from person to person. Some users report symptoms such as nausea, constipation, or fatigue, especially in the early stages of treatment. These effects, if persistent, could affect sleep quality. For example, gastrointestinal discomfort during the night may disrupt sleep cycles, and feelings of fatigue may mask deeper issues related to circadian misalignment. Patients are encouraged to report any persistent side effects to their healthcare provider, particularly if these are interfering with rest or daily functioning. In the UK, Mounjaro is approved for the treatment of Type 2 Diabetes, not explicitly for weight loss alone. It is available only by prescription and must be issued under the guidance of a qualified healthcare professional. Given the current MHRA regulations, medications like Mounjaro cannot be marketed directly for weight loss in the UK, even though weight reduction may be observed as a secondary effect. Patients interested in exploring whether Mounjaro for Type 2 Diabetes may be appropriate for their health situation should consult their GP or a specialist. Discussions should always be individualised, considering the full scope of metabolic health, including factors such as sleep. For those using Mounjaro as part of a diabetes management plan, here are a few practical strategies to enhance sleep: 1. Maintain a Regular Sleep Schedule Going to bed and waking up at the same time each day supports your circadian rhythm, which may also help stabilise hormone activity related to appetite and metabolism. 2. Limit Stimulants in the Evening Avoid caffeine, nicotine, or heavy meals close to bedtime. These can interfere with the quality of sleep and digestion—particularly important for individuals on medications affecting gastric emptying. 3. Mind the Timing of Mounjaro Injections Some patients find that the timing of the Mounjaro injection may influence when side effects like nausea or fatigue appear. Administering it at a time that allows side effects to resolve before sleep can be helpful. 4. Create a Sleep-Friendly Environment Cool temperatures, reduced light exposure, and a screen-free wind-down routine can all contribute to better sleep outcomes. 5. Stay Physically Active Regular, moderate exercise has been shown to improve sleep quality and enhance insulin sensitivity. It may also support the body's response to tirzepatide. When it comes to managing Type 2 Diabetes and supporting healthy weight outcomes, medications like Mounjaro offer a powerful tool. But pharmacological treatments rarely work in isolation. Lifestyle choices—especially adequate, high-quality sleep—can significantly influence the overall effectiveness of a treatment plan. By prioritising sleep hygiene alongside medication, physical activity, and nutrition, individuals may see more stable improvements in glucose regulation, appetite control, and body weight. As our understanding of the interplay between sleep and metabolic function continues to evolve, patients and healthcare providers alike should view rest not as a luxury, but as an essential part of therapeutic success. For patients who have been prescribed Mounjaro by a healthcare professional, Pharmacy Planet is a trusted UK-based online pharmacy offering regulated access to licensed treatments. You can buy Mounjaro, including the MounjaroKwikPen, through their platform following appropriate clinical assessment. They also provide additional information for those interested in buying tirzepatide compound under prescription. TIME BUSINESS NEWS
National Geographic
11 hours ago
- National Geographic
Diet soda might be making you hungrier
The idea that diet sodas can help you lose weight is becoming increasingly complicated as emerging research suggests they may confuse the brain—and trigger an urge to eat. Artificial sweeteners in diet sodas can potentially trigger brain activity linked to hunger, raising questions about their role in weight control. Photograph By Narong KHUEANKAEW/ Istock/Getty Images Millions of people reach for diet sodas each day to reduce sugar intake, manage their weight, or make healthier choices. But new research suggests these artificially sweetened drinks may do more than satisfy a sweet tooth—they may also be quietly rewiring how the brain regulates hunger. Artificial sweeteners have long been controversial for their possible link to cancer and poor gut health. Yet some studies suggest that sweeteners like sucralose may stimulate the regions of the brain involved in hunger signaling, potentially triggering the urge to eat. Whether that leads to actual weight gain is less clear, but the idea that diet sodas support weight loss is becoming increasingly complicated. What does sucralose do differently than sugar When you eat or drink something with calories—such as a sugary soda—your body initiates a cascade of responses designed to manage energy. Glucose is absorbed into the bloodstream, your gut releases hormones like GLP-1 and leptin, and your pancreas produces insulin. Together, these signals tell the hypothalamus—the brain's hunger-regulating command center—that energy has arrived, helping you feel full and satisfied. (The surprising reason we can't stop thinking about junk food.) But that feedback loop breaks down when artificial sweeteners like sucralose enter the picture. Such changes can be observed through functional MRI scans showing activity in the hypothalamus and its connections to other brain regions, says Kathleen Page, an endocrinologist and director of the Diabetes and Obesity Institute at the University of Southern California's Keck School of Medicine. 'We think [the activity] may be a biomarker of satiety signaling,' she says. Eating glucose typically causes a decrease in hypothalamic activity, which is associated with feelings of fullness. Sucralose, an artificial sweetener, seems to increase the activity in the brain region instead. Page's team tested this by giving 75 young adults beverages sweetened with either sucralose, sucrose (table sugar), or plain water. They found that sucralose-sweetened beverages increased blood flow to the hypothalamus and resulted in increased hunger, while sucrose-sweetened beverages reduced blood flow and hunger. And unlike sucrose, they found that artificial sweeteners didn't increase levels of insulin and GLP-1 in the blood—some of the hormones linked to promoting satiety. Previous studies on mice show similar results. One possible explanation? A disconnect between taste and nutrition. Sucralose is hundreds of times sweeter than sugar but contains no calories. 'When the brain gets a signal of sweetness, it's anticipating that nutrients will follow,' Page says. But when they don't, the mismatch might stimulate appetite 'because the brain is still looking for that nutrient,' Page says, adding that this phenomenon has been observed in mice, which crave more sugary foods after they've consumed an artificial sweetener. Naturally flavored sparkling waters offer a no-sugar, no-sweetener option that some experts recommend over diet sodas for curbing cravings. Photograph By Olga Yastremska/ Alamy Artificial sweeteners don't just affect the brain; they affect metabolism too. A 2020 study found that when sucralose was consumed alongside carbohydrates—which are broken down into glucose in the body—it impaired glucose metabolism by making participants less sensitive to insulin. 'By adding an artificial sweetener, you change the metabolic fate of the glucose,' says Dana Small, a neuroscientist and psychologist specializing in metabolism at McGill University in Montreal and lead researcher of the study. Although artificial sweeteners appear to disrupt these signals, the evidence on whether that leads to weight gain is mixed. Several large cohort studies have linked artificial sweeteners with an increased risk of obesity and weight gain. One recent study found those who drank diet beverages daily were more likely to develop type 2 diabetes. Other new results show that high consumption of diet beverages and saccharin (but not aspartame or sucralose) is linked to a greater risk of developing diabetes. Another 20-year study found people accumulated more body fat if they were more frequent consumers of sweeteners. (Low-calorie sweeteners might not be as good for us as we thought.) But correlation isn't causation. 'People who drink artificial sweeteners are more likely to be thinking about their weight,' Small says. 'Is the artificial sweetener causing the weight gain, or is it the weight gain causing the artificial sweetener use?' Still, international agencies have incorporated these results into their health recommendations. The World Health Organization cautioned against using artificial sweeteners for weight management in 2023, citing evidence that linked them to increased risk of obesity and type 2 diabetes. Randomized controlled trials have also produced conflicting results. Some show that replacing sugary drinks with artificial sweeteners, especially as part of a weight loss program, can lead to a modest amount of weight loss. But other evidence shows the opposite. Results presented at this year's American Diabetes Association meeting showed women with type 2 diabetes who swapped diet drinks with water were twice as likely to go into remission. They also lost about 4.5 pounds more than those who continued drinking the diet beverages. The role of hunger—and why it might not matter Even as studies show that artificial sweeteners may stimulate appetite, some researchers argue that hunger itself may not be the main reason we eat. 'It's not so common that we actually eat because we're hungry and stop eating because we're full,' says Richard D. Mattes, a nutrition scientist at Purdue University in Indiana. Boredom, craving a sensory experience, or being in a social setting are among the other reasons people might start eating. 'Hunger is a relatively minor contributor to that,' he says. (Addicted to diet soda? Here's the history of its low-calorie secret weapon.) Ideally, everyone would drink plain water. 'But the issue is, people choose to use a beverage to satisfy other desires for sensory stimulation,' Mattes says. If a low-calorie sweetened beverage replaces an energy-rich beverage and helps people comply with a diet, then it serves a function, he added. Still, others urge more caution given the mounting evidence on the adverse health effects of the beverages. Page counsels her patients with diabetes against both sugary drinks and artificially sweetened ones, given how sweet taste, regardless of the source, may increase appetite or trigger cravings. For those who can't give up the fizz of soda, she recommends naturally flavored carbonated waters instead. 'The bottom line is that artificial sweeteners are not inert like they were once thought to be,' Small says. 'And I think the bulk of the evidence suggests that they're not healthy.'
Los Angeles Times
12 hours ago
- Los Angeles Times
Severe obesity in U.S. children has more than tripled since 2008
The proportion of severely overweight children in the U.S. has skyrocketed in recent years, with the highest rates seen in adolescents and Black children, a new study found. Roughly 23% of all children were obese in 2023, up from 19% in 2008, according to the survey published this month in JAMA Network Open. Additionally, more than 1% of children between the ages of 2 and 18 had 'extremely severe obesity' — a 250% increase from the start of the study, the researchers from UC San Diego found. Phillipp Hartmann, the study's corresponding author, said he hopes the results lead to more trials that test the benefits of powerful weight loss drugs called GLP-1s for children and adolescents with severe obesity. 'It might be reasonable in those patients to have the weight loss medications very early,' he said in an interview. Medical professionals may be open to broadening the use of the popular weight loss drugs to treat obesity and diabetes in ever-younger patients. The Food and Drug Administration has approved only semaglutide, the main ingredient in Novo Nordisk's Ozempic and Wegovy, for children 12 and older. But weight-loss medicines have been tested on kids as young as 6. Severe obesity also came with a higher risk of other health complications, such prediabetes and diabetes, severe insulin resistance and metabolic syndrome — a cluster of conditions that can increase the chance of heart disease and stroke. The results were based on information from more than 25,000 children gathered as part of the National Health and Nutrition Examination Survey, which is managed by the Centers for Disease Control and Prevention and the National Center for Health Statistics. Amponsah writes for Bloomberg.
